Relmada Therapeutics Inc (RLMD) — Cash Flow-to-Debt Ratio
Relmada Therapeutics Inc (RLMD) has a Cash Flow-to-Debt Ratio of -1.95x as of December 2025, meaning its operating cash flow of $-14.60 Million could theoretically repay -2% of its total liabilities ($7.49 Million) in one year. See Relmada Therapeutics Inc (RLMD) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Relmada Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Relmada Therapeutics Inc across 15 annual periods. Also explore Relmada Therapeutics Inc (RLMD) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Relmada Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Relmada Therapeutics Inc. For market capitalisation and broader financial context, see how much is Relmada Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.11x | $-45.79 Million | $7.49 Million | ▼ -21.6% |
| 2024 | -5.03x | $-51.76 Million | $10.30 Million | ▼ -18.7% |
| 2023 | -4.24x | $-51.66 Million | $12.19 Million | ▲ +49.1% |
| 2022 | -8.32x | $-103.80 Million | $12.47 Million | ▼ -36.5% |
| 2021 | -6.10x | $-91.87 Million | $15.06 Million | ▼ -176.5% |
| 2020 | -2.21x | $-27.81 Million | $12.60 Million | ▼ -26501.5% |
| 2019 | -0.01x | $-12.09K | $1.46 Million | ▲ +98.8% |
| 2018 | -0.70x | $-6.00 Million | $8.56 Million | ▲ +85.1% |
| 2017 | -4.70x | $-6.47 Million | $1.38 Million | ▼ -14.4% |
| 2016 | -4.11x | $-13.14 Million | $3.20 Million | ▼ -294.2% |
| 2015 | -1.04x | $-16.23 Million | $15.58 Million | ▲ +0.0% |
| 2014 | -1.04x | $-16.23 Million | $15.58 Million | ▼ -1149.3% |
| 2014 | -0.08x | $-2.24 Million | $26.87 Million | ▼ -18788.6% |
| 2013 | 0.00x | $-11.86K | $26.87 Million | ▲ +100.0% |
| 2012 | -1.08x | $-7.57K | $7.00K | — |